Methotrexate

Antimetabolite — Oncology

• Drug Class: Antimetabolite
• Category: Oncology
• Type: Small Molecule
• SMILES: CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1

What is Methotrexate?

Methotrexate is a cornerstone medication in both oncology and the management of certain autoimmune diseases. As a potent antimetabolite, it functions by interfering with the body's metabolic processes, particularly those involving folic acid. This action makes it highly effective in rapidly dividing cells, a characteristic of both cancer cells and the inflammatory processes seen in conditions like rheumatoid arthritis and psoriasis. Available as a generic medication, it is also known by various brand names, including Rheumatrex, Trexall, and Rasuvo, depending on its formulation and intended use.

Developed in the late 1940s, methotrexate was initially synthesized as a chemotherapeutic agent. Its ability to inhibit dihydrofolate reductase (DHFR), an enzyme crucial for DNA synthesis, cell replication, and repair, quickly established its role in treating various cancers. Over time, its immunomodulatory properties were recognized, leading to its widespread use in treating chronic inflammatory conditions where an overactive immune system plays a significant role.

Generic vs. Brand Names

Methotrexate is widely available as a generic medication, which generally makes it more accessible and affordable. However, it is also marketed under several brand names, each often associated with specific formulations or indications:

• Rheumatrex Dose Pack: Typically used for rheumatoid arthritis and psoriasis, this formulation is designed for oral administration.
• Trexall: Approved for various cancers, including acute lymphoblastic leukemia, breast cancer, and head and neck cancers, as well as for rheumatoid arthritis and severe psoriasis. It is available in oral and injectable forms.
• Rasuvo: A brand name for an injectable form of methotrexate, often used for rheumatoid arthritis and psoriatic arthritis.
• Otrexup: Another brand name for a subcutaneous injection of methotrexate for rheumatoid arthritis.

The choice between generic and a specific brand often depends on physician preference, insurance coverage, and the specific clinical indication.

Mechanism of Action

Methotrexate's therapeutic effects stem from its potent inhibition of the enzyme dihydrofolate reductase (DHFR). DHFR is essential for the conversion of dihydrofolate to tetrahydrofolate (THF). Tetrahydrofolate is a vital coenzyme in one-carbon transfer reactions, which are indispensable for the synthesis of purines and pyrimidines – the building blocks of DNA and RNA. By blocking DHFR, methotrexate effectively depletes the intracellular pool of tetrahydrofolate, thereby:

• Inhibiting DNA Synthesis: The lack of purines and pyrimidines halts the de novo synthesis of DNA, preventing cell replication.
• Impacting RNA Synthesis: While the primary effect is on DNA, RNA synthesis can also be indirectly affected.
• Inducing Apoptosis: Cells, particularly rapidly dividing ones like cancer cells or activated immune cells, cannot sustain their growth and function without adequate DNA and RNA synthesis, leading to programmed cell death (apoptosis).

In the context of cancer, methotrexate targets rapidly proliferating tumor cells. In autoimmune diseases like rheumatoid arthritis, it targets the rapidly dividing lymphocytes and other immune cells that contribute to inflammation and joint damage. Methotrexate also exhibits anti-inflammatory properties beyond DHFR inhibition, potentially by increasing extracellular adenosine levels, which is a potent endogenous anti-inflammatory mediator.

Receptor Interactions and Molecular Targets

The primary molecular target of methotrexate is the enzyme dihydrofolate reductase (DHFR). Methotrexate acts as a competitive inhibitor of DHFR, binding to its active site with high affinity. This binding is significantly stronger than that of the natural substrate, dihydrofolate, effectively blocking the enzyme's catalytic activity. The binding is reversible but can be sustained due to the drug's slow dissociation from the enzyme.

While DHFR is the principal target, at higher concentrations, methotrexate can also inhibit other folate-dependent enzymes, such as thymidylate synthase and purine synthesis enzymes, further amplifying its cytotoxic and anti-proliferative effects. The molecule's structural similarity to folic acid allows it to occupy the binding site of DHFR.

Clinical Uses & Indications

Methotrexate is a versatile drug with a broad spectrum of clinical applications, spanning both malignant and non-malignant conditions. Its efficacy is attributed to its ability to disrupt the folate pathway, essential for cell proliferation.

Oncological Indications (FDA-Approved)

Methotrexate is a critical component of chemotherapy regimens for a variety of cancers. Its use in oncology is often dose-dependent, with higher doses required to achieve cytotoxic effects:

• Acute Lymphoblastic Leukemia (ALL): High-dose methotrexate is a standard treatment for ALL, often used in combination with other chemotherapeutic agents.
• Non-Hodgkin's Lymphoma: It is used in the treatment of certain types of lymphoma.
• Choriocarcinoma and Related Trophoblastic Diseases: Methotrexate is highly effective in treating these gestational trophoblastic tumors.
• Breast Cancer: Used in combination chemotherapy regimens for advanced breast cancer.
• Head and Neck Cancers: Effective in treating squamous cell carcinomas of the head and neck.
• Lung Cancer: Employed in the treatment of small cell and non-small cell lung cancers.
• Osteosarcoma: High-dose methotrexate is a crucial part of the treatment for osteosarcoma, particularly in adjuvant and neoadjuvant settings.

Non-Oncological Indications (FDA-Approved)

In lower doses, methotrexate exerts potent immunomodulatory and anti-inflammatory effects, making it a go-to treatment for several chronic autoimmune and inflammatory conditions:

• Rheumatoid Arthritis (RA): It is considered a disease-modifying antirheumatic drug (DMARD) and is often the first-line therapy for moderate to severe RA.
• Psoriasis: Used for severe, recalcitrant psoriasis that has not responded to other treatments.
• Psoriatic Arthritis: Effective in managing the joint inflammation associated with psoriasis.
• Crohn's Disease: Used off-label in some regions and approved in others for maintaining remission and reducing corticosteroid dependence in Crohn's disease.
• Ectopic Pregnancy: Methotrexate can be used to treat unruptured ectopic pregnancies, particularly in hemodynamically stable patients.

Dosage & Administration

The dosage and administration of methotrexate vary significantly depending on the condition being treated, the patient's weight and body surface area, renal function, and whether it is used for oncological or non-oncological purposes. It can be administered via several routes:

Common Dosage Forms and Routes

• Oral: Tablets are commonly used for rheumatoid arthritis, psoriasis, and certain oncological indications (e.g., ALL maintenance). Doses are typically taken once weekly.
• Intramuscular (IM): Injections can be given into the muscle, often used for RA or when oral absorption is a concern.
• Intravenous (IV): Administered directly into a vein, used for high-dose chemotherapy regimens in oncology. This route requires careful monitoring and often includes leucovorin rescue.
• Subcutaneous (SC): Injections under the skin are common for RA and psoriatic arthritis, offering an alternative to oral or IM routes. Pre-filled syringes and auto-injectors are available.
• Intrathecal (IT): Injection into the cerebrospinal fluid (CSF) via lumbar puncture is used to treat or prevent central nervous system (CNS) involvement in certain leukemias and lymphomas. This route requires preservative-free formulations.

Dosage Considerations

For Rheumatoid Arthritis/Psoriasis: Dosing usually starts low (e.g., 10-15 mg once weekly) and is gradually increased based on response and tolerance, typically not exceeding 25-30 mg per week. It is crucial to emphasize that oral or IM/SC methotrexate for these conditions is taken once weekly, not daily. Daily dosing can lead to severe toxicity.

For Oncology: Doses can range from relatively low (e.g., 2.5 mg/m² daily for ALL maintenance) to very high (e.g., 1 g/m² or more for osteosarcoma or CNS lymphoma). High-dose methotrexate requires careful monitoring of drug levels and often necessitates leucovorin rescue. Leucovorin (folinic acid) is a reduced folate that bypasses the DHFR block, replenishing tetrahydrofolate levels and protecting healthy tissues from methotrexate toxicity.

Renal function is a critical determinant of methotrexate clearance. Impaired kidney function can lead to prolonged drug levels and severe toxicity. Patients on methotrexate should be closely monitored for hematologic, hepatic, and renal toxicity.

Side Effects & Safety

Methotrexate, like all medications, can cause side effects, ranging from mild to severe. The incidence and severity often depend on the dose, duration of treatment, and individual patient factors. Close medical supervision is essential during treatment.

Common Side Effects

These are generally manageable and may decrease over time or with dose adjustments:

• Gastrointestinal: Nausea, vomiting, diarrhea, stomatitis (mouth sores), abdominal pain.
• Hematologic: Mild leukopenia (low white blood cell count), thrombocytopenia (low platelet count), anemia.
• Dermatologic: Rash, itching, photosensitivity.
• General: Fatigue, headache, dizziness.

Serious Side Effects

These require immediate medical attention:

• Severe Bone Marrow Suppression: Leading to significant risk of infection (severe leukopenia) and bleeding (severe thrombocytopenia).
• Hepatotoxicity: Liver function abnormalities, fibrosis, cirrhosis (especially with long-term use or high doses). Regular liver function tests are mandatory.
• Nephrotoxicity: Kidney damage, particularly with high doses or in patients with pre-existing renal impairment.
• Pulmonary Toxicity: Methotrexate pneumonitis (inflammation of the lungs), which can be serious and even fatal. Symptoms include dry cough, shortness of breath, and fever.
• Mucositis: Severe inflammation and ulceration of the mucous membranes, particularly in the mouth and gut.
• Neurologic Toxicity: Particularly with intrathecal administration, can include headache, back pain, nausea, vomiting, and potentially more severe neurological deficits.
• Skin Reactions: Severe skin reactions like Stevens-Johnson syndrome or toxic epidermal necrolysis are rare but life-threatening.

Contraindications and Precautions

Methotrexate is contraindicated in patients with:

• Known hypersensitivity to methotrexate.
• Severe renal impairment.
• Severe hepatic impairment.
• Significant pre-existing hematologic abnormalities, such as marked bone marrow hypoplasia, leukopenia, thrombocytopenia, or significant anemia.
• Active infections.
• Immunodeficiency syndromes.
• Pregnancy and breastfeeding (it is a known teratogen). Effective contraception is essential for both men and women of reproductive potential during and for a period after treatment.

Important Note: Patients taking methotrexate for non-oncological conditions (e.g., RA, psoriasis) should be educated about the critical difference between weekly dosing and daily dosing. Accidental daily intake can lead to severe, life-threatening toxicity.

Drug Interactions

Methotrexate can interact with numerous medications, potentially increasing its toxicity or reducing its efficacy. Careful review of all concomitant medications is essential before initiating methotrexate therapy.

Notable Interactions

• Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Concurrent use, especially with high-dose methotrexate, can increase methotrexate plasma levels by impairing renal excretion and potentially displace it from plasma proteins, leading to increased toxicity. Low-dose methotrexate for RA may sometimes be co-administered with NSAIDs, but requires careful monitoring.
• Penicillins and Cephalosporins: These antibiotics can interfere with the renal tubular secretion of methotrexate, potentially leading to elevated serum concentrations and toxicity.
• Sulfonamides (e.g., Trimethoprim/Sulfamethoxazole): Can inhibit dihydrofolate reductase themselves and may also displace methotrexate from plasma proteins or impair renal excretion, increasing toxicity risk.
• Probenecid: A uricosuric agent that can inhibit the renal excretion of methotrexate.
• Proton Pump Inhibitors (PPIs): Some studies suggest a potential interaction, particularly with high-dose methotrexate, possibly due to impaired renal excretion.
• Vitamin Supplements: High doses of folic acid or folinic acid (unless prescribed as leucovorin rescue) can antagonize the effects of methotrexate, particularly in cancer therapy. However, folic acid supplementation is often recommended for patients on low-dose methotrexate for RA or psoriasis to mitigate certain side effects, but this should be under strict medical guidance.
• Live Vaccines: Concurrent administration is generally contraindicated due to the risk of severe or fatal infections from the vaccine.
• Theophylline: Methotrexate can decrease the clearance of theophylline.

Always inform your healthcare provider about all medications, supplements, and herbal products you are taking before starting or continuing methotrexate therapy.

Molecular Properties

Understanding the molecular characteristics of methotrexate is fundamental to comprehending its behavior and interactions within biological systems.

Chemical Structure and Formula

Methotrexate is a synthetic folate analog. Its chemical structure is designed to mimic folic acid, enabling it to bind to dihydrofolate reductase (DHFR). The molecule consists of a pteridine ring system linked to a p-aminobenzoic acid moiety, which is further connected to an L-glutamic acid residue. The key difference from folic acid is the presence of a methyl group on the nitrogen at position 10 (N10) and the replacement of the hydroxyl group at position 4 with an amine group.

Molecular Formula: C₂₀H₂₂N₈O₅

Molecular Weight: Approximately 454.44 g/mol

SMILES Notation

The Simplified Molecular Input Line Entry System (SMILES) provides a linear notation for describing the structure of chemical molecules. For Methotrexate, the SMILES string is:

CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1

This notation encodes the connectivity of atoms and the types of bonds within the molecule. It is a crucial tool for computational chemistry, drug design, and database searching.

Structure Description

The structure can be conceptually divided into three main parts:

• Pteridine Ring System: A fused pyrimidine and pyrazine ring, essential for binding to DHFR. The two amine groups (at positions 2 and 4) are critical for this interaction.
• p-Aminobenzoic Acid (PABA) Moiety: Connects the pteridine ring to the glutamic acid residue via an amide linkage. The nitrogen atom at position 10 is methylated.
• L-Glutamic Acid Residue: A dicarboxylic acid that enhances water solubility and influences cellular uptake and retention. The polyglutamation of methotrexate within cells can further increase its intracellular retention and binding affinity to DHFR and other folate-dependent enzymes.

The specific arrangement of these functional groups dictates methotrexate's potent inhibitory activity against DHFR and its overall pharmacological profile.

Analyze Methotrexate with MolForge

Methotrexate stands as a testament to the power of molecular design in medicine, impacting the treatment of numerous life-threatening and chronic conditions. Its complex mechanism of action, diverse clinical applications, and critical safety considerations highlight the intricate balance required in therapeutic intervention. For researchers and pharmaceutical professionals aiming to unlock the full potential of molecules like methotrexate, or to discover novel therapeutics with improved profiles, advanced computational tools are indispensable.

MolForge's AI-powered platform offers state-of-the-art capabilities for molecular analysis, property prediction, and virtual screening. By leveraging sophisticated algorithms and vast datasets, MolForge can help you delve deeper into the characteristics of methotrexate, predict its interactions, explore potential new indications, or design next-generation analogs. Discover how our intelligent tools can accelerate your drug discovery journey. Explore Methotrexate and countless other molecules in detail on the MolForge platform today by visiting our dashboard.